Structures by: Tumanov N.
Total: 102
N-[(2E)-10-(4-chlorophenyl)-3-[(4-chlorophenyl)amino]-2,10-dihydrophenazin-2-ylidene]propan-2-aminium methanol 2-{2-[(2-chloro-6-methylphenyl)amino]phenyl}acetate
C27H23Cl2N4,C14H10Cl2NO2,0.491(CH4O),C0.25H1.02O0.25
CrystEngComm (2020)
a=16.7209(3)Å b=17.2504(5)Å c=27.8319(7)Å
α=90° β=93.438(2)° γ=90°
Pentakis(1-phenylpropan-1-one) bis(N-[(2E)-10-(4-chlorophenyl) -3-[(4-chlorophenyl)amino]-2,10-dihydrophenazin-2-ylidene] propan-2-aminium) bis(2-{2-[(2,6-dichlorophenyl)amino]phenyl} acetate)
2(C27H23Cl2N4),2(C14H10Cl2NO2),5(C9H10O)
CrystEngComm (2020)
a=10.7319(4)Å b=13.6005(6)Å c=21.5496(9)Å
α=73.502(4)° β=77.404(4)° γ=73.540(4)°
Clofaziminium 1+ diclofenac 1- diclofenac salt cocrystal
C27H23Cl2N41,C14H10Cl2NO21,C14H11Cl2NO2
CrystEngComm (2020)
a=11.9326(3)Å b=15.2549(4)Å c=16.0042(4)Å
α=89.161(2)° β=70.570(2)° γ=69.693(2)°
Clofaziminium diclofenac
C27H23Cl2N41,C14H10Cl2NO21
CrystEngComm (2020)
a=12.4461(6)Å b=13.2751(5)Å c=13.3667(6)Å
α=84.423(3)° β=67.963(4)° γ=66.662(4)°
Nonakis(2-hydroxybenzaldehyde) tetrakis(N-[(2E)-10- (4-chlorophenyl)-3-[(4-chlorophenyl)amino]-2,10- dihydrophenazin-2-ylidene]propan-2-aminium) tetrakis(2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetate) hydrate
4(C27H23Cl2N4),4(C14H10Cl2NO2),9(C7H6O2),H2O
CrystEngComm (2020)
a=10.4132(5)Å b=21.2266(7)Å c=25.0657(7)Å
α=66.238(3)° β=89.969(3)° γ=86.658(3)°
N-[(2E)-10-(4-chlorophenyl)-3-[(4-chlorophenyl)amino]-2,10- dihydrophenazin-2-ylidene] propan-2-aminium acetonitrile 2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetate dihydrate
C27H23Cl2N4,C14H10Cl2NO2,C2H3N,2(H2O)
CrystEngComm (2020)
a=11.6515(3)Å b=11.7149(3)Å c=16.0793(4)Å
α=103.558(2)° β=90.461(2)° γ=105.250(2)°
Clofaziminium diclofenac (1-) diclofenac salt cocrystal
C27H23Cl2N41,C14H10Cl2NO21,C14H11Cl2NO2
CrystEngComm (2020)
a=10.8837(2)Å b=14.4737(3)Å c=17.7519(4)Å
α=101.568(2)° β=105.173(2)° γ=94.286(2)°
N-[(2E)-10-(4-chlorophenyl)-3-[(4-chlorophenyl)amino] -2,10-dihydrophenazin-2-ylidene]propan-2-aminium ethanol 2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetate
C27H23Cl2N4,C14H10Cl2NO2,C2H6O
CrystEngComm (2020)
a=12.5818(4)Å b=13.4486(3)Å c=13.5318(3)Å
α=80.291(2)° β=71.638(2)° γ=71.710(2)°
Clofaziminium 1+ diclofenac 1- diclofenac ethylacetate solvate
C27H23Cl2N4,C14H10Cl2NO2,C14H11Cl2NO2,C4H8O2
CrystEngComm (2020)
a=15.0569(4)Å b=15.3773(4)Å c=15.4247(4)Å
α=76.043(2)° β=61.975(3)° γ=63.541(3)°
Pentakis(1-phenylpropan-1-one) bis(N-[(2E)-10-(4-chlorophenyl) -3-[(4-chlorophenyl)amino]-2,10-dihydrophenazin-2-ylidene] propan-2-aminium) bis(2-{2-[(2,6-dichlorophenyl)amino]phenyl} acetate)
2(C27H23Cl2N4),2(C14H10Cl2NO2),5(C9H10O)
CrystEngComm (2020)
a=10.5086(4)Å b=13.4783(5)Å c=21.4224(8)Å
α=73.629(3)° β=76.913(3)° γ=73.271(3)°
Clofaziminium 1+ diclofenac 1- diclofenac acetonitrile solvated cocrystal of salt
C27H23Cl2N4,C14H10Cl2NO2,C14H11Cl2NO2,2(C2H3N)
CrystEngComm (2020)
a=15.0694(11)Å b=15.2735(10)Å c=15.5991(13)Å
α=74.882(7)° β=61.685(8)° γ=64.227(7)°
CaCl2 Levetiracetam Nicotinamide
C22H36CaN6O6,2(Cl)
Chemical communications (Cambridge, England) (2020) 56, 86 13229-13232
a=11.9243(5)Å b=8.0669(3)Å c=15.4348(7)Å
α=90° β=92.338(4)° γ=90°
CaCl2 Levetiracetam Isonicotinamide
C22H36CaN6O6,2(Cl)
Chemical communications (Cambridge, England) (2020) 56, 86 13229-13232
a=7.93030(11)Å b=15.1768(2)Å c=23.7226(3)Å
α=90° β=90° γ=90°
RS-naproxen D-proline 1:1 cocrystal, polymorph I
2(C14H14O3),2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=12.1578(5)Å b=5.8278(2)Å c=25.6828(14)Å
α=90° β=98.762(5)° γ=90°
S-naproxen L-proline 1:1 cocrystal, polymorph II
2(C14H14O3),2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=16.2991(7)Å b=5.8654(3)Å c=18.6876(9)Å
α=90° β=100.052(4)° γ=90°
RS-naproxen DL-proline 1:1 cocrystal, polymorph I
C14H14O3,C5H9NO2
CrystEngComm (2018) 20, 45 7308
a=9.9964(3)Å b=9.0958(4)Å c=39.9654(15)Å
α=90° β=90° γ=90°
RS-naproxen D-proline 1:1 cocrystal, polymorph II
2(C14H14O3),2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=12.5901(6)Å b=5.7587(3)Å c=51.425(3)Å
α=90° β=90° γ=90°
RS-naproxen L-proline 1:1 cocrystal, polymorph III
2(C14H14O3),2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=12.705(2)Å b=5.7631(8)Å c=25.000(5)Å
α=90° β=95.041(11)° γ=90°
S-naproxen ethanol solvate
C14H14O3,C2H6O
CrystEngComm (2018) 20, 45 7308
a=5.9273(2)Å b=8.7713(5)Å c=28.0747(15)Å
α=90° β=90° γ=90°
1:1 RS-naproxen D-proline cocrystal methanol solvate
2(C14H14O3),2(C5H9NO2),CH4O
CrystEngComm (2018) 20, 45 7308
a=12.9532(4)Å b=5.76337(15)Å c=25.2764(6)Å
α=90° β=93.984(3)° γ=90°
S-naproxen DL-proline 1:2 cocrystal
C14H14O3,2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=5.8836(7)Å b=9.0952(18)Å c=44.047(10)Å
α=90° β=90° γ=90°
S-naproxen DL-proline 1:1 cocrystal
2(C14H14O3),2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=8.84337(19)Å b=5.83510(15)Å c=33.6766(7)Å
α=90° β=91.9839(19)° γ=90°
RS-naproxen DL-proline 1:1 cocrystal, polymorph II
C14H14O3,C5H9NO2
CrystEngComm (2018) 20, 45 7308
a=34.537(4)Å b=9.0077(8)Å c=5.7183(5)Å
α=90° β=90° γ=90°
1:1 S-naproxen DL-proline cocrystal hydrate
2(C14H14O3),2(C5H9NO2),2(H2O1)
CrystEngComm (2018) 20, 45 7308
a=6.06468(13)Å b=12.2629(3)Å c=50.6290(15)Å
α=90° β=90° γ=90°
S-naproxen L-proline 2:3 cocrystal
2(C14H14O3),3(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=5.70180(10)Å b=18.8609(3)Å c=37.2392(5)Å
α=90° β=90° γ=90°
S-naproxen L-proline 1:2 cocrystal
C14H14O3,2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=5.88160(7)Å b=8.79809(10)Å c=45.4679(5)Å
α=90° β=90° γ=90°
C19H20NO,Cl
C19H20NO,Cl
CrystEngComm (2018) 20, 24 3318
a=8.3825(4)Å b=14.3515(8)Å c=13.3425(7)Å
α=90° β=96.835(5)° γ=90°
C19H20NO,Br
C19H20NO,Br
CrystEngComm (2018) 20, 24 3318
a=8.3080(4)Å b=13.9039(8)Å c=13.6580(6)Å
α=90° β=96.642(4)° γ=90°
C23H22NO,NO3
C23H22NO,NO3
CrystEngComm (2018) 20, 24 3318
a=14.9120(4)Å b=6.9922(2)Å c=37.2099(13)Å
α=90° β=90° γ=90°
C19H20NO,NO3
C19H20NO,NO3
CrystEngComm (2018) 20, 24 3318
a=10.4953(9)Å b=19.9612(19)Å c=8.1903(7)Å
α=90° β=90° γ=90°
C20H22NO21,Cl1,2(H2O)
C20H22NO21,Cl1,2(H2O)
CrystEngComm (2018) 20, 24 3318
a=11.5183(3)Å b=24.4350(7)Å c=7.1002(2)Å
α=90° β=98.786(3)° γ=90°
C20H22NO2,NO3,H2O
C20H22NO2,NO3,H2O
CrystEngComm (2018) 20, 24 3318
a=10.9418(7)Å b=22.2438(13)Å c=8.0740(6)Å
α=90° β=99.632(7)° γ=90°
Tetrakis(2-[(E)-2-(2-hydroxy-3-methoxyphenyl)ethenyl]-1,3,3-trimethyl-3H-indol-1-ium) tris(phosphoric acid) nonahydrate tetradihydrogen phosphate
2(C20H22NO2),2(H2O4P),1.5(H3O4P),4.5(H2O)
CrystEngComm (2018) 20, 24 3318
a=12.0289(5)Å b=12.4435(5)Å c=17.4047(7)Å
α=76.128(4)° β=81.814(4)° γ=79.953(4)°
C23H22NO1,Cl1
C23H22NO1,Cl1
CrystEngComm (2018) 20, 24 3318
a=17.6960(6)Å b=15.1030(4)Å c=6.9665(3)Å
α=90° β=92.410(4)° γ=90°
2-[(E)-2-(2-hydroxy-3-methoxyphenyl)ethenyl]-1,3,3-trimethyl-3H-indol-1-ium dihydrate bromide
C20H22NO21,Br1,2(H2O)
CrystEngComm (2018) 20, 24 3318
a=11.5976(3)Å b=23.9015(6)Å c=7.36093(15)Å
α=90° β=98.766(2)° γ=90°
C19H21BrNO1.50
C19H21BrNO1.50
CrystEngComm (2018) 20, 24 3318
a=12.8779(5)Å b=10.4911(5)Å c=12.8498(7)Å
α=90° β=94.836(4)° γ=90°
2-[(E)-2-(2-hydroxy-5-nitrophenyl)ethenyl]-1,3,3-trimethyl-3H-indol-1-ium hydrogen sulfate
C19H19N2O3,HO4S
CrystEngComm (2018) 20, 24 3318
a=11.768(3)Å b=25.295(5)Å c=7.006(2)Å
α=90° β=104.70(3)° γ=90°
C19H19N2O3,NO3
C19H19N2O3,NO3
CrystEngComm (2018) 20, 24 3318
a=7.227(3)Å b=10.0542(10)Å c=12.687(3)Å
α=80.825(14)° β=89.00(2)° γ=88.089(18)°
C19H17N3O5
C19H17N3O5
CrystEngComm (2018) 20, 24 3318
a=18.8741(12)Å b=6.2632(3)Å c=14.2571(7)Å
α=90° β=98.548(6)° γ=90°
C23H22NO,Br
C23H22NO,Br
CrystEngComm (2018) 20, 24 3318
a=17.8583(18)Å b=15.1686(10)Å c=6.9757(3)Å
α=90° β=93.704(7)° γ=90°
C20H22NO2,HO4S
C20H22NO2,HO4S
CrystEngComm (2018) 20, 24 3318
a=7.8327(5)Å b=16.0190(13)Å c=15.1017(19)Å
α=90° β=90° γ=90°
4(C19H19N2O3),2(H3O4P),4(H2O4P),4(C2H3N),H2O
4(C19H19N2O3),2(H3O4P),4(H2O4P),4(C2H3N),H2O
CrystEngComm (2018) 20, 24 3318
a=12.6562(3)Å b=13.9654(7)Å c=28.3803(12)Å
α=83.572(4)° β=79.127(3)° γ=78.777(3)°
1,3,5-trifluoro-2,4,6-triiodobenzene; 2-[(1E)-[(pyridin-3-yl)imino]methyl]phenol 1:1 cocrystal
C12H10N2O,C6F3I3
CrystEngComm (2018) 20, 36 5332
a=24.1738(4)Å b=9.45562(19)Å c=17.8360(3)Å
α=90° β=90° γ=90°
C19H11F4I2NO
C19H11F4I2NO
CrystEngComm (2018) 20, 36 5332
a=5.3298(5)Å b=5.9839(4)Å c=15.276(2)Å
α=90.196(8)° β=93.824(9)° γ=100.428(7)°
2(C12H10N2O),C6F3I3
2(C12H10N2O),C6F3I3
CrystEngComm (2018) 20, 36 5332
a=4.1899(3)Å b=29.106(2)Å c=24.6798(18)Å
α=90° β=92.834(7)° γ=90°
1,2,4,5-tetrafluoro-3,6-diiodobenzene 2-[(1E)-[(pyridin-3-yl)imino]methyl]phenol 1:2 cocrystal
C12H10N2O,0.5(C6F4I2)
CrystEngComm (2018) 20, 36 5332
a=15.3516(5)Å b=5.75781(16)Å c=16.8675(6)Å
α=90° β=105.671(3)° γ=90°
1,2,3,5-tetrafluoro-4,6-diiodobenzene 2-[(1E)-[(pyridin-3-yl)imino]methyl]phenol 1:1 cocrystal
C12H10N2O,C6F4I2
CrystEngComm (2018) 20, 36 5332
a=7.2968(5)Å b=15.2068(12)Å c=19.3646(15)Å
α=110.783(7)° β=91.701(6)° γ=100.999(6)°
C38H38Br4N2O2Zn2
C38H38Br4N2O2Zn2
CrystEngComm (2019) 21, 33 4925
a=9.3000(8)Å b=9.3023(8)Å c=11.3137(10)Å
α=94.166(7)° β=108.407(8)° γ=96.344(7)°
C46H42Cl4N2O2Zn2,C3H6O
C46H42Cl4N2O2Zn2,C3H6O
CrystEngComm (2019) 21, 33 4925
a=8.8991(3)Å b=13.0969(4)Å c=19.8630(6)Å
α=90° β=90.033(3)° γ=90°
C19H18Cl2N2O3Zn
C19H18Cl2N2O3Zn
CrystEngComm (2019) 21, 33 4925
a=17.659(4)Å b=15.216(3)Å c=6.9834(12)Å
α=90° β=94.06(2)° γ=90°
C19H18Cl3N2O3Zn,C19H19N2O3
C19H18Cl3N2O3Zn,C19H19N2O3
CrystEngComm (2019) 21, 33 4925
a=11.8909(7)Å b=12.6582(7)Å c=25.0471(16)Å
α=90° β=98.073(6)° γ=90°
C19H20Cl2N2O4Zn,2(H2O)
C19H20Cl2N2O4Zn,2(H2O)
CrystEngComm (2019) 21, 33 4925
a=12.388(6)Å b=13.671(7)Å c=14.855(8)Å
α=108.02(5)° β=101.20(4)° γ=101.01(4)°
Zinc(2+) ion 2-[(E)-2-(3-methoxy-2-oxidophenyl)ethenyl]-1,3,3-trimethyl-3H-indol-1-ium ethanol dibromide
C20H20NO2,Zn2,2(Br1),C2H6O1
CrystEngComm (2019) 21, 33 4925
a=10.1512(3)Å b=12.0717(4)Å c=21.8754(7)Å
α=84.876(3)° β=77.406(2)° γ=65.333(3)°
Zinc(2+) ion bis(1,3,3-trimethyl-2-[(E)-2-(5-nitro-2-oxidophenyl)ethenyl]-3H-indol-1-ium) dichloride
2(C19H18N2O3),Zn2,2Cl1
CrystEngComm (2019) 21, 33 4925
a=8.86510(16)Å b=14.8667(4)Å c=15.2523(5)Å
α=113.831(3)° β=94.587(2)° γ=91.7161(19)°
Dizinc(2+) ion bis(1,3,3-trimethyl-2-[(E)-2-(2-oxidonaphthalen-1-yl)ethenyl]-3H-indol-1-ium) tetrabromide acetone solvate
C46H42Br4N2O2Zn2,C3H6O
CrystEngComm (2019) 21, 33 4925
a=8.97440(14)Å b=12.9849(2)Å c=20.5608(3)Å
α=90° β=91.4476(14)° γ=90°
2(C22H27Cl2NO3Zn),H2O
2(C22H27Cl2NO3Zn),H2O
CrystEngComm (2019) 21, 33 4925
a=21.9384(11)Å b=9.7692(4)Å c=21.2029(10)Å
α=90° β=97.634(5)° γ=90°
C19H18Br2N2O3Zn
C19H18Br2N2O3Zn
CrystEngComm (2019) 21, 33 4925
a=17.517(7)Å b=15.290(4)Å c=7.252(2)Å
α=90° β=92.47(3)° γ=90°
C19H20Cl2N2O4Zn,2(H2O)
C19H20Cl2N2O4Zn,2(H2O)
CrystEngComm (2019) 21, 33 4925
a=6.5663(8)Å b=15.8090(12)Å c=20.1333(15)Å
α=90° β=90° γ=90°
2(C21H21Br2N3O3Zn),C2H3N
2(C21H21Br2N3O3Zn),C2H3N
CrystEngComm (2019) 21, 33 4925
a=14.4022(7)Å b=13.0338(6)Å c=26.6165(16)Å
α=90° β=99.770(6)° γ=90°
2(C19H19N2O3),Cl4Co,H2O
2(C19H19N2O3),Cl4Co,H2O
CrystEngComm (2019) 21, 33 4925
a=11.6156(11)Å b=13.0124(6)Å c=14.0058(14)Å
α=77.862(6)° β=76.661(8)° γ=87.030(6)°
C19H18Cl3CoN2O3,C19H19N2O3
C19H18Cl3CoN2O3,C19H19N2O3
CrystEngComm (2019) 21, 33 4925
a=11.9195(9)Å b=12.6137(7)Å c=25.1143(14)Å
α=90° β=97.136(6)° γ=90°
C20.07H21.22Br2.46N2O3.54Zn,C19H18.46N2O3
C20.07H21.22Br2.46N2O3.54Zn,C19H18.46N2O3
CrystEngComm (2019) 21, 33 4925
a=11.8302(4)Å b=12.7363(3)Å c=24.6870(9)Å
α=90° β=98.600(3)° γ=90°
Clofaziminium (1+) diclofenac (1-) ethanol solvate
C27H23Cl2N4,C14H10Cl2NO2,C2H6O
CrystEngComm (2020)
a=12.5325(5)Å b=13.1139(3)Å c=13.1773(4)Å
α=82.032(2)° β=71.833(3)° γ=74.538(3)°
CaCl2 etiracetam Isonicotinamide
C22H36CaN6O6,2(Cl)
Chemical communications (Cambridge, England) (2020) 56, 86 13229-13232
a=7.968(2)Å b=12.170(4)Å c=15.304(4)Å
α=87.17(2)° β=86.30(2)° γ=74.76(2)°
RS-naproxen L-proline 1:2 cocrystal
C14H14O3,2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=5.84172(9)Å b=8.98394(13)Å c=45.6816(8)Å
α=90° β=90° γ=90°
C19H20NO,Cl3H2OZn
C19H20NO,Cl3H2OZn
CrystEngComm (2019) 21, 33 4925
a=8.2890(5)Å b=21.5395(16)Å c=12.2257(11)Å
α=90° β=97.748(7)° γ=90°
C38H36Br2N4O6Zn
C38H36Br2N4O6Zn
CrystEngComm (2019) 21, 33 4925
a=9.1737(6)Å b=14.9690(14)Å c=15.421(2)Å
α=116.717(11)° β=98.405(8)° γ=89.487(7)°
Triammine Calcium Dodecahydro-closo-dodecaborate
B12H122,3(H3N),Ca2
Dalton Trans. (2017)
a=11.86978(18)Å b=11.86978(18)Å c=16.7977(5)Å
α=90.00000° β=90.00000° γ=120.00000°
Diammine Disodium Dodecahydro-closo-dodecaborate
B12H122,2(H3N),2(Na1)
Dalton Trans. (2017)
a=7.16723(11)Å b=7.16723(11)Å c=7.15737(19)Å
α=90.00000° β=90.00000° γ=120.00000°
Tetraammine Dilithium Dodecahydro-closo-dodecaborate
B12H122,4(H3N),2(Li1)
Dalton Trans. (2017)
a=8.4122(3)Å b=9.5193(5)Å c=9.6434(5)Å
α=90.00000° β=99.472(4)° γ=90.00000°
Tetraammine Disodium Dodecahydro-closo-dodecaborate
B12H122,4(H3N),2(Na1)
Dalton Trans. (2017)
a=8.6875(2)Å b=9.4168(3)Å c=9.9096(3)Å
α=90.00000° β=98.3296(18)° γ=90.00000°
S-naproxen L-alanine
C14H14O3,C3H7NO2
CrystEngComm (2014) 16, 35 8185
a=5.05836(11)Å b=7.1121(3)Å c=45.2723(17)Å
α=90° β=90° γ=90°
S-naproxen D-alanine
C14H14O3,C3H7NO2
CrystEngComm (2014) 16, 35 8185
a=5.3366(4)Å b=6.9013(6)Å c=44.227(4)Å
α=90° β=90° γ=90°
S-naproxen D-tyrosine
C14H14O3,C9H11NO3
CrystEngComm (2014) 16, 35 8185
a=9.4508(4)Å b=5.9725(2)Å c=18.9525(7)Å
α=90.00000° β=103.814(2)° γ=90.00000°
S-naproxen L-alanine
C14H14O3,C3H7NO2
CrystEngComm (2014) 16, 35 8185
a=5.05836(11)Å b=7.1121(3)Å c=45.2723(17)Å
α=90° β=90° γ=90°
S-naproxen D-alanine
C14H14O3,C3H7NO2
CrystEngComm (2014) 16, 35 8185
a=5.3366(4)Å b=6.9013(6)Å c=44.227(4)Å
α=90° β=90° γ=90°
S-naproxen D-tryptophan monohydrate
C14H14O3,C11H12N2O2,H2O
CrystEngComm (2014) 16, 35 8185
a=5.88418(16)Å b=11.3844(3)Å c=34.6863(9)Å
α=90° β=90° γ=90°
S-naproxen D-tyrosine
C14H14O3,C9H11NO3
CrystEngComm (2014) 16, 35 8185
a=9.4508(4)Å b=5.9725(2)Å c=18.9525(7)Å
α=90.00000° β=103.814(2)° γ=90.00000°
4,10-Dimethoxy-13-(pyridin-3-yl)-6<i>H</i>,12<i>H</i>-6,12-epiminodibenzo[<i>b</i>,<i>f</i>][1,5]dithiocine methanol 0.463-solvate
C21H18N2O2S2,0.463(CH4O)
Acta Crystallographica Section C Structural Chemistry (2020) 76, 3
a=14.7387(4)Å b=16.6445(3)Å c=17.8970(4)Å
α=84.662(2)° β=73.498(2)° γ=68.886(2)°
Clofaziminium hydrogen fumarate
C27H23Cl2N4,C4H3O4
Acta Crystallographica Section B (2019) 75, 4
a=7.47882(9)Å b=26.0041(3)Å c=14.78241(16)Å
α=90° β=102.5075(12)° γ=90°
Clofaziminium hydrogen succinate
C27H23Cl2N4,C4H5O4
Acta Crystallographica Section B (2019) 75, 4
a=10.6376(6)Å b=12.2781(5)Å c=12.7975(8)Å
α=90.079(4)° β=113.211(6)° γ=108.284(4)°
Clofaziminium saccharinate acetonitrile solvate
C27H23Cl2N4,C7H4NO3S,1.393(C2H3N)
Acta Crystallographica Section B (2019) 75, 4
a=7.9970(3)Å b=13.5824(3)Å c=16.6638(7)Å
α=80.214(3)° β=80.034(4)° γ=83.036(3)°
Clofaziminium saccharinate
C34H27Cl2N5O3S
Acta Crystallographica Section B (2019) 75, 4
a=8.2115(7)Å b=13.5327(12)Å c=14.325(3)Å
α=89.040(10)° β=88.864(10)° γ=83.781(7)°
Clofaziminium 2,4-dihydroxybenzoate methanol solvate
C27H23Cl2N4,C7H5O4,C1H4O
Acta Crystallographica Section B (2019) 75, 4
a=9.4861(4)Å b=12.5322(5)Å c=15.3641(5)Å
α=98.415(3)° β=103.379(3)° γ=110.450(4)°
Bis-clofaziminium terephthalate terephthalic acid
C27H23Cl2N4,0.5C8H4O42,0.5C8H6O4
Acta Crystallographica Section B (2019) 75, 4
a=11.7990(4)Å b=12.0736(4)Å c=14.6803(5)Å
α=72.472(3)° β=80.688(3)° γ=72.030(3)°
Bis-clofaziminium terephthalate terephthalic acid
C27H23Cl2N4,0.5C8H4O42,0.5C8H6O4
Acta Crystallographica Section B (2019) 75, 4
a=10.4028(3)Å b=10.8454(3)Å c=15.4229(5)Å
α=71.183(3)° β=73.984(3)° γ=76.148(2)°
C8H14N2O2,C6H10O4
C8H14N2O2,C6H10O4
Crystal Growth & Design (2014) 14, 6 2880
a=12.9082(9)Å b=11.5417(8)Å c=12.5179(9)Å
α=90.00° β=116.342(9)° γ=90.00°
Levetiracetam 2,2-dimethylsuccinic acid cocrystal
C8H14N2O2,C6H10O4
Crystal Growth & Design (2014) 14, 6 2880
a=6.23877(7)Å b=11.55362(12)Å c=11.34360(12)Å
α=90.00000° β=90.9259(9)° γ=90.00000°
C8H14N2O2,C7H6O4
C8H14N2O2,C7H6O4
Crystal Growth & Design (2014) 14, 6 2880
a=6.2828(3)Å b=13.3843(6)Å c=18.7984(8)Å
α=90.00° β=96.638(4)° γ=90.00°
Etiracetam 2,4-dihydroxybenzoic acid cocrystal
C8H14N2O2,C7H6O4
Crystal Growth & Design (2014) 14, 6 2880
a=6.60584(3)Å b=13.11919(7)Å c=18.80723(8)Å
α=90.00000° β=90.00000° γ=90.00000°
C8H14N2O2,C7H5NO4
C8H14N2O2,C7H5NO4
Crystal Growth & Design (2014) 14, 6 2880
a=5.8455(2)Å b=11.6845(12)Å c=12.5762(10)Å
α=78.856(8)° β=82.443(6)° γ=84.035(7)°
C8H14N2O2,2(C7H5NO4)
C8H14N2O2,2(C7H5NO4)
Crystal Growth & Design (2014) 14, 6 2880
a=8.0511(4)Å b=13.0536(6)Å c=23.0243(9)Å
α=90.00° β=90.00° γ=90.00°
C8H14N2O2,2(C7H5NO4)
C8H14N2O2,2(C7H5NO4)
Crystal Growth & Design (2014) 14, 6 2880
a=24.2697(8)Å b=7.4683(2)Å c=13.3230(5)Å
α=90.00° β=104.663(4)° γ=90.00°
2(C7H5NO4),C8H14N2O2
2(C7H5NO4),C8H14N2O2
Crystal Growth & Design (2014) 14, 6 2880
a=7.0988(9)Å b=7.3613(10)Å c=12.1428(13)Å
α=77.496(10)° β=88.250(10)° γ=74.232(12)°
C8H14N2O2,C2H2O4
C8H14N2O2,C2H2O4
Crystal Growth & Design (2014) 14, 6 2880
a=5.7253(2)Å b=20.2528(7)Å c=10.9457(5)Å
α=90.00° β=100.085(4)° γ=90.00°
C8H14N2O2,C2H2O4
C8H14N2O2,C2H2O4
Crystal Growth & Design (2014) 14, 6 2880
a=5.7646(4)Å b=19.8963(14)Å c=11.0690(8)Å
α=90.00° β=99.331(6)° γ=90.00°
9-thionobenzoate-10-phosphatriptycene
C26H17O2PS
The Journal of organic chemistry (2019) 84, 17 11268-11274
a=25.0052(2)Å b=8.40856(8)Å c=20.01476(18)Å
α=90° β=94.2309(8)° γ=90°
9-phosphatriptycene triphenylcarbenium tetrafluoroborate complex
C38H28P1,BF41
The Journal of organic chemistry (2019) 84, 17 11268-11274
a=13.4876(2)Å b=13.4876(2)Å c=57.4638(16)Å
α=90° β=90° γ=120°
9-phosphatriptycene
C19H13P
The Journal of organic chemistry (2019) 84, 17 11268-11274
a=14.8144(10)Å b=8.1417(3)Å c=13.0081(9)Å
α=90° β=120.325(10)° γ=90°
9-phosphatriptycene
C19H13P
The Journal of organic chemistry (2019) 84, 17 11268-11274
a=15.0310(5)Å b=8.2009(2)Å c=13.1609(4)Å
α=90° β=120.422(4)° γ=90°